Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

equate supplies of Vancocin to meet

demand for the product;

-- changes in prescribing or procedural practices of infectious disease,

gastroenterology and internal medicine doctors, including off-label

prescribing of other products;

-- actions by the FDA, the Internal Revenue Service or other government

regulatory agencies;

-- decreases in the rate of infections for which Vancocin is prescribed;

-- decrease in the sensitivity of the relevant bacteria to Vancocin;

-- changes in terms required by wholesalers, including fee-for-service

contracts;

-- the timing and results of anticipated events in the Company's CMV, NTCD

and HCV programs; and

-- the timing and nature of potential business development activities

related to the Company's efforts to expand its current portfolio

through in-licensing or other means of acquiring products in clinical

development or marketed products.

There can be no assurance that NTCD will one day be the therapy of choice for recurrent CDI, that recurrence of CDI will remain a significant medical need in CDI patients, that ViroPharma will conduct additional HCV studies in the future, that FDA or EMEA will not require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval of any of its product candidates, or that ViroPharma will be successful in gaining regulatory approval of any of its product candidates. These factors, and other factors, including, but not limited to those described in ViroPharma's quarterly reports on Form 10-Q filed with the Securities and Exchange Commission during 2007, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. ViroPharma to Present at the Maxim Group First Annual Growth Conference
2. ViroPharma to Present at the UBS Global Life Sciences Conference
3. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
4. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
5. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
6. ViroPharma Augments Senior Management
7. ViroPharma Provides Update on Vancocin(R)
8. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
9. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
10. Accuray Incorporated to Report First Quarter Fiscal Year 2008 Financial Results
11. Aflac Incorporated to Release Third Quarter Results On October 23, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing for the ... USPI Tenet Health. , The American Heart Association hosts their well-known Heart Walk to ... that together, a difference can be made. Walkers can participate in the cause and ...
(Date:8/28/2015)... , ... August 28, 2015 , ... The 6th ... renowned Brain Aneurysm Foundation has added yet another accolade to its cadre of widespread ... , “With the help of the medical community and the University of ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... high grade protein with zero fat, carbs, sugar, gluten, lactose or caffeine in ... finalist for the 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer packaged ...
(Date:8/28/2015)... FL. (PRWEB) , ... August 28, 2015 , ... ... for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach on ... that it should begin with the employer and employees getting together for meaningful ...
(Date:8/28/2015)... Jordan, Utah (PRWEB) , ... August 28, 2015 ... ... been awarded a three-year accreditation for its adolescent residential, counseling, day treatment and ... demonstrates that it meets international standards for quality and its pursuit of excellence. ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2
... Journal of Sports Medicine says that a woman's sporting ... fingers//. Researchers said that the finding could provide an ... to serious disease, intellectual ability, certain personality traits, and ... this area has so far focused exclusively on men. ...
... funding of ?850,000 is likely to improve the current ... septic shock and cancer//. The project, which is to ... mathematicians at the University of Bath. It will examine ... in whole body scanning. ,They hope that electron ...
... could detect hidden fractures once a person wears it//. ... at Purdue University in Indiana contain sensors which pick up ... damaged bones, reported the online edition of Daily Mail. ... rest so that the injured bone is given a chance ...
... the risk of developing lung cancer although the effect is ... over 200 women under the age of 80 with primary ... Teeside, northeast England, reported Newswise wire. ,Rates of ... of England, where heavy industries expanded rapidly throughout the 19th ...
... infected with kala azar, the deadly black fever, as ... endemic to the region. // ,Experts running ... Health Organisation (WHO) and working to develop affordable drugs ... infected with kala azar. ,"It's affecting the ...
... French surgeons took off on a specially equipped aircraft early ... operation // carried out in weightless conditions, the Bordeaux ... is equipped with a special surgical module, which could serve ... out in the gravity-free conditions of outer space. ...
Cached Medicine News:Health News:New Research Could Improve Knowledge Of Serious Illnesses 2Health News:Bihar Districts Affected by Black Fever 2Health News:Bihar Districts Affected by Black Fever 3
(Date:8/28/2015)... , Aug. 28, 2015  IP Shakti, LLC, today announced ... Logo - ... "Our new corporate identity signifies our transformation into a ... predictive analytics platform for patent claim validity." ... of the proprietary AIA Shield™ platform, the Company commenced a ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015  Perrigo Company ... that it has completed the acquisition of leading OTC ... at €200 million. The transaction is a clear demonstration ... the Company,s leading European distribution network spanning 36 countries.  ... Joseph C. Papa commented, "We are excited to ...
(Date:8/28/2015)... England and PITTSBURGH ... MYL ) today announced that its shareholders ... plc (NYSE: PRGO ; TASE) and the ... shareholders at an extraordinary general meeting of shareholders ... the votes cast at the extraordinary general meeting. ...
Breaking Medicine Technology:IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
... From Its Metabolic Disease Program In Clinical ... ... ) announced today it has initiated a,Phase 1 study of ISIS 325568, ... 2 diabetes by inhibiting production,of the glucagon receptor (GCGR). GCGR is a ...
... Calif., Sept. 4 Quark Pharmaceuticals, Inc., a,clinical-stage ... interference-based therapeutics, announced today that,J. Joseph Marr, M.D. ... Medical,Officer. In this capacity, Dr. Marr will ... programs and in outlining the goals and plans ...
Cached Medicine Technology:Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes 2Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes 3Quark Pharmaceuticals Appoints New Chief Medical Officer 2Quark Pharmaceuticals Appoints New Chief Medical Officer 3Quark Pharmaceuticals Appoints New Chief Medical Officer 4
Grab one and go, One of the smallest handheld oximeters available, Datex-Ohmeda s TuffSat is the ideal spot-check solution for hospital, home care, transport, and EMS. TuffSat comes fully loaded wi...
The Stat Profile pHOx CO-Oximeter is intended for use in those situations where a more comprehensive profile beyond the measured hematocrit, hemoglobin, and SO2% offered by the Stat Profile pHOx ...
Smith & Nephew's CDS System is developed exclusively for discography., Developed exclusively for discography, it is the first system designed to measure true disc pressure and record real-time proce...
Maxi-Therm® hyper-hypothermia water blankets from Cincinnati Sub-Zero are designed for single-patient use. These blankets are easy to clean, stain resistant and ideal for isolation cases....
Medicine Products: